New radiopharmaceutical enters testing

Article

Draxis Health of Mississauga, ON, has gotten the nod from Canadian officials to begin clinical trails of a radiopharmaceutical designed to image difficult-to-diagnose infections. The radiopharmaceutical promises to selectively distinguish infection from

Draxis Health of Mississauga, ON, has gotten the nod from Canadian officials to begin clinical trails of a radiopharmaceutical designed to image difficult-to-diagnose infections. The radiopharmaceutical promises to selectively distinguish infection from inflammation by binding directly with bacteria. It combines the widely used antibacterial agent ciprofloxacin with technetium-99m.Enrollment in the study is scheduled to begin in January. The Phase I study, to be conducted at Hôpital Hotel-Dieu, Centre Hospitalier de L'Université de Montréal, will involve 10 healthy subjects. Whole-body images will be taken periodically after injection of the drug to visualize its distribution throughout the body over time.

Recent Videos
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Can AI Assessment of Longitudinal MRI Scans Improve Prediction for Pediatric Glioma Recurrence?
A Closer Look at MRI-Guided Adaptive Radiotherapy for Monitoring and Treating Glioblastomas
Incorporating CT Colonography into Radiology Practice
What New Research Reveals About Computed Tomography and Radiation-Induced Cancer Risk
What New Interventional Radiology Research Reveals About Treatment for Breast Cancer Liver Metastases
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Related Content
© 2025 MJH Life Sciences

All rights reserved.